#Canada #Mississauga #Mint Pharmaceuticals #Bayer Canada #ADALAT XL

Mint Pharmaceuticals Partners with Bayer Canada

Mint Pharmaceuticals Inc. has recently entered into a strategic partnership with Bayer Canada to handle the distribution of ADALAT® XL® (nifedipine extended-release tablets) 30 mg in the Canadian market. This partnership, effective from September 3, 2025, represents a significant step in ensuring uninterrupted access to essential medications for Canadian patients.

ADALAT® XL® has been authorized for sale in Canada since 1995 and is widely used for managing chronic stable angina and mild to moderate essential hypertension. The collaboration between Mint and Bayer aims to enhance the availability and accessibility of this important medication for healthcare providers and patients alike.

Jaiveer Singh, CEO of Mint Pharmaceuticals, expressed enthusiasm about the new partnership, stating, "Canadian patients and healthcare professionals depend on uninterrupted access to vital medicines, and that responsibility drives everything we do at Mint. By partnering with Bayer, we are reinforcing our shared commitment to reliability, quality, and patient care." Singh emphasized the strength of Mint’s well-established supply chain, developed over the past 15 years, which will facilitate the effective distribution of ADALAT® XL® across Canada.

Viktoria Friedrich, Country President and General Manager of Bayer Inc.’s Pharmaceutical Division, shared her perspective on the collaboration, highlighting Bayer's excitement about joining forces with a company known for its quality and customer service. She remarked, "This partnership will enable us to leverage Mint's extensive distribution network and expertise in the Canadian market, ensuring that ADALAT® XL® remains readily available to those who need it."

Both companies are fully committed to maintaining high distribution standards, ensuring healthcare professionals and patients can count on the timely availability of ADALAT® XL®. The collaboration reinforces the shared mission of Mint Pharmaceuticals and Bayer Canada to prioritize patient well-being and healthcare excellence.

About Mint Pharmaceuticals

Mint Pharmaceuticals is a Canadian-owned manufacturer recognized for producing high-quality, affordable generic medicines. Over the past decade, Mint has successfully prevented 23 national drug shortages affecting 16 essential medicines, showcasing its resilience and commitment to safeguarding patient access to necessary medications. In 2024, Mint celebrated a milestone by launching its 100th molecule in Canada and has received accolades from Deloitte as one of Canada’s Best Managed Companies for several consecutive years, attaining Platinum Club status in 2025. Mint is a proud member of the Canadian Generic Pharmaceutical Association (CGPA).

About Bayer

Bayer is a global company that operates in healthcare and nutrition, engaging with its mission of “Health for all, Hunger for none.” The organization aims to address the challenges posed by an increasing global population through innovative solutions. As of fiscal 2024, Bayer employed approximately 93,000 individuals and reported sales of €46.6 billion, reflecting its commitment to sustainable development and impactful innovation. For more information about Bayer’s initiatives and products, visit bayer.ca.